Skip to main content
. Author manuscript; available in PMC: 2009 Sep 15.
Published in final edited form as: Cancer. 2008 Sep 15;113(6):1370–1378. doi: 10.1002/cncr.23691

Table 2.

Matching of Patients with Myeloid Sarcoma with Patients with Acute Myeloid Leukemia Treated with Cytarabine-Containing Therapies

Patient Cytogenetics Age Zubrod
PS
Year
of
Treatment
Event-free
Survival
(weeks)
Overall
Survival
(weeks)
MS1 +8 64 2 1990 8 18
M1 for MS1 +8 67 1 1991 2 2
M2 for MS1 +8 67 1 1991 5 5
M3 for MS1 +8 67 1 1992 19 34
M4 for MS1 +8 65 2 1994 9 9
M5 for MS1 +8 65 0 1994 45 68
M6 for MS1 +8 66 1 1995 44 60
M7 for MS1 +8 62 0 1995 10 10
M8 for MS1 +8 61 1 1997 39 43
M9 for MS1 +8 64 1 1997 12 12
M10 for MS1 * +8 67 2 1996 3 3
M11 for MS1 ** +8 67 1 1996 6 178
MS2 Normal 53 1 1991 16 22
M1 for MS2 11Q 52 1 1991 5 5
M2 for MS2 INV 16 50 0 1994 572 572+
MS3 +8 57 0 1991 26 42+
M1 for MS3 +8 58 1 1995 545 545+
M2 for MS3 +8 58 2 1995 63 127
M3 for MS3 +8 59 2 1996 159 263
M4 for MS3 +8 57 1 1998 47 65
MS4 +8 70 1 1992 9 9+
M1 for MS4 +8 70 1 1993 655 655+
M2 for MS4 +8 71 1 1995 0 0
M3 for MS4 +8 69 1 1993 183 258
M4 for MS4 +8 68 1 1993 31 40
M5 for MS4 +8 73 1 1995 29 51
M6 for MS4 +8 72 0 1996 68 85
M7 for MS4 +8 73 2 1997 2 2
M8 for MS4 +8 68 1 1998 10 25
M9 for MS4 +8 73 2 1998 6 223
M10 for MS4 +8 68 1 1999 128 168+
M11 for MS4 +8 72 2 1999 4 4
M12 for MS4 * +8 67 2 1996 3 3
M13 for MS4 ** +8 67 1 1996 6 178
MS5 Normal 45 0 1994 36 36+
M1 for MS5 11Q 46 1 1998 3 58
M2 for MS5 T(8,21) 45 1 1996 6 6
M3 for MS5 +8 46 1 1999 3 3
MS6 Normal 31 1 1994 350 350+
M1 for MS6 T(8,21) 30 1 1996 105 170
M2 for MS6 11Q 30 1 1997 15 15
M3 for MS6 +8 34 1 1998 5 50
MS7 DEL 12 69 0 1995 71 71
M1 for MS7 MISC 67 1 1999 148 323
M2 for MS7 MISC 72 1 1996 103 272
M3 for MS7 MISC 71 1 1996 3 3
M4 for MS7 MISC 69 1 1997 5 5
M5 for MS7 MISC 68 2 1997 3 3
M6 for MS7 MISC 72 0 1997 37 64
M7 for MS7 MISC 72 1 1998 6 51
M8 for MS7 MISC 68 2 1999 5 43
M9 for MS7 MISC 70 1 1999 23 23
M10 for MS7 MISC 70 2 1999 1 1
M11 for MS7 MISC 72 2 2000 168 168
M12 for MS7 MISC 67 2 2000 22 24
M13 for MS7 MISC 69 1 2000 3 35
M14 for MS7 MISC 66 1 2000 3 29
M15 for MS7 MISC 69 1 2000 4 4
M16 for MS7 MISC 71 1 2002 7 24
M17 for MS7 MISC 68 1 2001 12 24
M18 for MS7 MISC 67 0 2002 166 166+
M19 for MS7 MISC 66 1 2002 8 21
M20 for MS7 MISC 70 1 2002 9 25
M21 for MS7 MISC 68 1 2002 31 161+
MS8 INV 16 57 0 1995 357+ 357+
M1 for MS8 INV 16 55 1 2001 245+ 245+
M2 for MS8 T(8,21) 56 1 2001 182+ 182+
M3 for MS8 INV 16 59 1 2002 79 147+
MS9 Normal 48 1 1995 255+ 255+
M1 for MS9 11Q 49 1 1998 23 23
M2 for MS9 +8 50 1 1998 61 63
M3 for MS9 T(8,21) 51 1 2001 46 46
MS10 Normal 59 1 1997 4 4
M1 for MS10 INV 16 59 1 2003 125 125+
M2 for MS10 *** +8 59 0 2003 42 90
MS11 Normal 60 0 1998 154+ 155+
M1 for MS11 +8 62 1 2003 4 4
M2 for MS11 +8 57 2 2001 8 8
M3 for MS11 +8 57 1 2002 92 134+
M4 for MS11 *** +8 59 0 2003 42 90
MS12 Normal 25 1 1998 44+ 45+
M1 for MS12 11Q 25 1 1995 529+ 529+
M2 for MS12 INV 16 23 1 2002 59 117
MS13 INV 16 47 0 1998 128+ 128+
M1 for MS13 INV 16 44 2 2001 27 81
M2 for MS13 INV 16 44 1 2001 216+ 216+
M3 for MS13 INV 16 49 0 2001 201+ 201+
M4 for MS13 INV 16 44 1 2002 156+ 156+
M5 for MS13 T(8,21) 47 1 2002 37 85
M6 for MS13 T(8,21) 47 0 2004 38+ 38+
M7 for MS13 T(8,21) 48 2 2004 66 118+
M8 for MS13 T(8,21) 49 1 2001 334+ 334+
M9 for MS13 T(8,21) 50 1 2001 81 222+
M10 for MS13 T(8,21) 50 1 2002 18 71
M11 for MS13 T(8,21) 50 1 2003 121+ 121+
MS14 Normal 71 1 2000 12 17
M1 for MS14 +8 69 1 2003 12 77
M2 for MS14 +8 69 2 2000 3 5
M3 for MS14 +8 71 1 2001 4 44
M4 for MS14 +8 74 1 2001 3 4
M5 for MS14 +8 69 0 2003 6 12
M6 for MS14 +8 70 1 2001 33 64
M7 for MS14 +8 74 0 2002 4 18
M8 for MS14 +8 72 1 2002 20 20
M9 for MS14 +8 69 1 2003 12 37
M10 for MS14 +8 73 2 2003 2 2
M11 for MS14 +8 68 0 2003 6 86
M12 for MS14 +8 74 1 2004 4 11

Abbreviations: MS=myeloid sarcoma, M = match (with acute myeloid leukemia)

*

This AML patient matches two different MS patients.

**

This AML patient matches two different MS patients.

***

This AML patient matches two different MS patients.